Portal de Periódicos da CAPES

Improvement of SARS‐CoV‐2 symptoms following Guselkumab injection in a psoriatic patient

2020; Wiley; Volume: 34; Issue: 8 Linguagem: Inglês

10.1111/jdv.16590

1468-3083

Farida Benhadou, V. del Mármol,

COVID-19 Clinical Research Studies

Journal of the European Academy of Dermatology and VenereologyVolume 34, Issue 8 p. e363-e364 Letter to the Editor Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient F. Benhadou, Corresponding Author F. Benhadou [email protected] [email protected] orcid.org/0000-0002-4533-8297 Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium Correspondence: F. Benhadou. E-mails: [email protected]; [email protected]Search for more papers by this authorV. del Marmol, V. del Marmol Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, BelgiumSearch for more papers by this author F. Benhadou, Corresponding Author F. Benhadou [email protected] [email protected] orcid.org/0000-0002-4533-8297 Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium Correspondence: F. Benhadou. E-mails: [email protected]; [email protected]Search for more papers by this authorV. del Marmol, V. del Marmol Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, BelgiumSearch for more papers by this author First published: 07 May 2020 https://doi.org/10.1111/jdv.16590Citations: 27Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16468 10.1111/jdv.16468 PubMedWeb of Science®Google Scholar 2Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017; 77: 855–862. 10.1016/j.jaad.2017.06.153 CASPubMedWeb of Science®Google Scholar 3Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 2020; 20: 277–277. 10.1038/s41577-020-0305-6 CASPubMedGoogle Scholar 4Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034. 10.1016/S0140-6736(20)30628-0 CASPubMedWeb of Science®Google Scholar 5Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–417. 10.1016/j.jaad.2016.11.041 CASPubMedWeb of Science®Google Scholar 6Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol 2020; 20: 271–272. 10.1038/s41577-020-0312-7 CASPubMedWeb of Science®Google Scholar 7Lebwohl M, Rivera-Oyola R, Murrell DF. Reply to "COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: a word of caution". J Am Acad Dermatol 2020; 82 :e215. https://doi.org/10.1016/j.jaad.2020.03.103 10.1016/j.jaad.2020.03.103 CASPubMedWeb of Science®Google Scholar Citing Literature Volume34, Issue8August 2020Pages e363-e364 This article also appears in:JEADV COVID-19 articles ReferencesRelatedInformation